Screener
Kura Oncology KURA Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Kura Oncology’s reported figures.
Based on the most recent quarter.
The source filing: Kura Oncology’s 10-Q, filed May 12, 2026. Open the filing →
- Filed
- May 12, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219481
FAQ
- What is Kura Oncology's debt-to-equity?
- Kura Oncology (KURA) reported debt-to-equity of 0.2× in Q1 2026.
- How has Kura Oncology's debt-to-equity changed year-over-year?
- Kura Oncology's debt-to-equity increased by 323.7% year-over-year, from 0.1× to 0.2×.
- What is the long-term trend for Kura Oncology's debt-to-equity?
- Over 5 years (2020 to 2025), Kura Oncology's debt-to-equity has grown at a 36.8% compound annual growth rate (CAGR), from 0× to 0.1×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Kura Oncology's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude